CytoReason
CytoReason has made a series of recent hires following signed deals with three of the top eight global pharma companies.
The company, which provides machine learning for drug discovery and development, has more than doubled the size of its team and increased revenues by 1,000% over the last 12 months.
Read: Quantified ‘immune age’ could transform drug development, disease management
Among the new hires includes the company’s first chief financial officer, Nurit Reder, who was most recently CFO of Glilot Capital Partners and vice president of operations at Wix.
Professor Gilad Silberberg, an expert in systems biology, also has joined CytoReason to lead bioinformatics for the company’s largest collaboration. He previously led bioinformatics and data analysis at Sweden’s Karolinska Institutet Department of Medicine Rheumatology Unit.
Leading strategic product development and innovation is Dr. Chanan Rubin, a US National Cancer Institute post-doc fellow. Chanan was previously core technologies director at Evogene and is a board member of the Israeli Society for Bioinformatics and Computational Biology.
Dr. Eitan Winter also has joined CytoReason as a senior bioinformatician scientist for major collaborations. Winter is a former research fellow at Cancer Research UK.